Heart Failure: Kalaiselvan Ot

Heart Failure
Kalaiselvan ot
Definition:
 A state in which the heart cannot
provide sufficient cardiac output to
satisfy the metabolic needs of the body
 It is commonly termed congestive heart

failure (CHF) since symptoms of
increase venous pressure are often
prominent
Etiology
 It is a common end point for many
diseases of cardiovascular system
 It can be caused by :
-Inappropriate work load (volume or pressure

overload)
-Restricted filling
-Myocyte loss
Causes of left ventricular
failure
• Volume over load: Regurgitate valve
High output status
• Pressure overload: Systemic hypertension
Outflow obstruction
• Loss of muscles: Post MI, Chronic ischemia
Connective tissue diseases
Infection, Poisons
(alcohol,cobalt,Doxorubicin)
• Restricted Filling: Pericardial diseases, Restrictive

cardiomyopathy, tachyarrhythmia
Pathophysiology
 Hemodynamic changes
 Neurohormonal changes
 Cellular changes
Hemodynamic changes
 From hemodynamic stand point HF can

be secondary to systolic dysfunction or
diastolic dysfunction
Neurohormonal changes
N/H changes Favorable effect Unfavor. effect
 HR , contractility, Arteriolar constriction 

 Sympathetic activity vasoconst.   V return, After load  workload
 filling  O2 consumption
 Renin-Angiotensin – Salt & water retention VR Vasoconstriction 

 after load
Aldosterone
 Vasopressin Same effect Same effect
 interleukins &TNF May have roles in myocyte Apoptosis

hypertrophy
Vasoconstriction VR  After load

Endothelin
Cellular changes
 Changes in Ca+2 handling.
 Changes in adrenergic receptors:
• Slight  in α1 receptors
• β1 receptors desensitization  followed by down regulation
 Changes in contractile proteins

 Program cell death (Apoptosis)
 Increase amount of fibrous tissue
Symptoms
• SOB, Orthopnea, paroxysmal nocturnal
dyspnea
• Low cardiac output symptoms
• Abdominal symptoms: Anorexia,nausea,

abdominal fullness,
Rt hypochondrial pain
Physical Signs
 High diastolic BP & occasional decrease in
systolic BP (decapitated BP)
 JVD
 Rales (Inspiratory)
 Displaced and sustained apical impulses
 Third heart sound – low pitched sound that is heard
during rapid filling of ventricle
Physical signs (cont.)
 Mechanism of S3 sudden deceleration of blood
as elastic limits of the ventricles are
reached
 Vibration of the ventricular wall by blood

filling
 Common in children
Physical signs (cont.)
 Fourth heart Sound (S4)
- Usually at the end of diastole
- Exact mechanism is not known
Could be due to contraction of
atrium against stiff ventricle
 Pale, cold sweaty skin

Framingham Criteria for
Dx of Heart Failure
 Major Criteria:
 PND
 JVD
 Rales
 Cardiomegaly
 Acute Pulmonary Edema
 S3 Gallop
 Positive hepatic Jugular reflex
 ↑ venous pressure > 16 cm H2O
Dx of Heart Failure (cont.)
 Minor Criteria
LL edema,
Night cough
Dyspnea on exertion
Hepatomegaly
Pleural effusion
↓ vital capacity by 1/3 of normal
Tachycardia 120 bpm
Weight loss 4.5 kg over 5 days management
Forms of Heart Failure
 Systolic & Diastolic

 High Output Failure
 Pregnancy, anemia, thyrotoxisis, A/V fistula,
Beriberi, Pagets disease
 Low Output Failure
 Acute
 large MI, aortic valve dysfunction---
 Chronic
Forms of heart failure
( cont.)
 Right vs Left sided heart failure:
Right sided heart failure :
Most common cause is left sided failure
Other causes included : Pulmonary embolisms
Other causes of pulmonary htn.
RV infarction
MS
Usually presents with: LL edema, ascites
hepatic congestion
cardiac cirrhosis (on the long run)
Differential diagnosis
 Pericardial diseases
 Liver diseases
 Nephrotic syndrome
 Protein losing enteropathy
Laboratory Findings
 Anemia
 Hyperthyroid
 Chronic renal insuffiency, electrolytes
abnormality
 Pre-renal azotemia
 Hemochromatosis
Electrocardiogram
 Old MI or recent MI
 Arrhythmia
 Some forms of Cardiomyopathy are
tachycardia related
 LBBB→may help in management
Chest X-ray
 Size and shape of heart

 Evidence of pulmonary venous congestion
(dilated or upper lobe veins → perivascular
edema)
 Pleural effusion
Echocardiogram
 Function of both ventricles

 Wall motion abnormality that may signify CAD
 Valvular abnormality
 Intra-cardiac shunts
Cardiac Catheterization
 When CAD or valvular is suspected
 If heart transplant is indicated

TREATMENT
 Correction of reversible causes
 Ischemia
 Valvular heart disease
 Thyrotoxicosis and other high output status
 Shunts
 Arrhythmia
 A fib, flutter, PJRT
 Medications
 Ca channel blockers, some antiarrhythmics
Diet and Activity
 Salt restriction
 Fluid restriction
 Daily weight (tailor therapy)
 Gradual exertion programs
Diuretic Therapy
 The most effective symptomatic relief
 Mild symptoms
 HCTZ
 Chlorthalidone
 Metolazone
 Block Na reabsorbtion in loop of henle and distal
convoluted tubules
 Thiazides are ineffective with GFR < 30 --/min
Diuretics (cont.)
 Side Effects
 Pre-renal azotemia
 Skin rashes
 Neutropenia
 Thrombocytopenia
 Hyperglycemia
 ↑ Uric Acid
 Hepatic dysfunction
Diuretics (cont.)
 More severe heart failure → loop
diuretics
 Lasix (20 – 320 mg QD), Furosemide
 Bumex (Bumetanide 1-8mg)
 Torsemide (20-200mg)
Mechanism of action: Inhibit chloride reabsortion in ascending limb of
loop of Henle results in natriuresis, kaliuresis and metabolic alkalosis
Adverse reaction:
pre-renal azotemia
Hypokalemia
Skin rash
ototoxicity
K+ Sparing Agents
 Triamterene & amiloride – acts on distal tubules
to ↓ K secretion
 Spironolactone (Aldosterone inhibitor)
recent evidence suggests that it may improve
survival in CHF patients due to the effect on renin-
angiotensin-aldosterone system with subsequent
effect on myocardial remodeling and fibrosis
Inhibitors of renin-angiotensin-
aldosterone system
 Renin-angiotensin-aldosterone system is activation

early in the course of heart failure and plays an
important role in the progression of the syndrome
 Angiotensin converting enzyme inhibitors
 Angiotensin receptors blockers
 Spironolactone
Angiotensin Converting
Enzyme Inhibitors
 They block the R-A-A system by inhibiting the
conversion of angiotensin I to angiotensin II
→ vasodilation and ↓ Na retention
 ↓ Bradykinin degradation ↑ its level → ↑ PG
secretion & nitric oxide
 Ace Inhibitors were found to improve survival
in CHF patients
 Delay onset & progression of HF in pts with
asymptomatic LV dysfunction
 ↓ cardiac remodeling
Side effects of ACE
inhibitors
 Angioedema
 Hypotension
 Renal insuffiency
 Rash
 cough
Angiotensin II receptor
blockers
 Has comparable effect to ACE I
 Can be used in certain conditions when ACE I

are contraindicated (angioneurotic edema,
cough)
Digitalis Glycosides
(Digoxin, Digitoxin)
 The role of digitalis has declined somewhat
because of safety concern
 Recent studies have shown that digitals does
not affect mortality in CHF patients but
causes significant
 Reduction in hospitalization
 Reduction in symptoms of HF
Digitalis (cont.)
Mechanism of Action
 +ve inotropic effect by ↑ intracellular Ca &
enhancing actin-myosin cross bride formation
(binds to the Na-K ATPase → inhibits Na
pump → ↑ intracellular Na → ↑ Na-Ca
exchange
 Vagotonic effect
 Arrhythmogenic effect
Digitalis Toxicity
 Narrow therapeutic to toxic ratio
 Non cardiac manifestations

Anorexia,
Nausea, vomiting,
Headache,
Xanthopsia sotoma,
Disorientation
Digitalis Toxicity
 Cardiac manifestations
 Sinus bradycardia and arrest
 A/V block (usually 2nd degree)
 Atrial tachycardia with A/V Block
 Development of junctional rhythm in patients with
a fib
 PVC’s, VT/ V fib (bi-directional VT)
Digitalis Toxicity
Treatment
 Hold the medications
 Observation
 In case of A/V block or severe bradycardia →
atropine followed by temporary PM if needed
 In life threatening arrhythmia → digoxin-
specific fab antibodies
 Lidocaine and phenytoin could be used – try
to avoid D/C cardioversion in non life
threatening arrhythmia
β Blockers
 Has been traditionally contraindicated in pts
with CHF
 Now they are the main stay in treatment on
CHF & may be the only medication that
shows substantial improvement in LV function
 In addition to improved LV function multiple
studies show improved survival
 The only contraindication is severe
decompensated CHF
Vasodilators
 Reduction of afterload by arteriolar
vasodilatation (hydralazin)  reduce LVEDP, O2
consumption,improve myocardial perfusion,  stroke
volume and COP
 Reduction of preload By venous dilation
( Nitrate)  ↓ the venous return ↓ the load on
both ventricles.
 Usually the maximum benefit is achieved by
using agents with both action.
Positive inotropic agents
 These are the drugs that improve myocardial
contractility (β adrenergic agonists, dopaminergic
agents, phosphodiesterase inhibitors),
dopamine, dobutamine, milrinone, amrinone
 Several studies showed ↑ mortality with oral
inotropic agents
 So the only use for them now is in acute
sittings as cardiogenic shock
Anticoagulation
(coumadine)
 Atrial fibrillation
 H/o embolic episodes
 Left ventricular apical thrombus

Antiarrhythmics
 Most common cause of SCD in these patients

is ventricular tachyarrhythmia
 Patients with h/o sustained VT or SCD → ICD

implant
Antiarrhythmics (cont.)
 Patients with non sustained ventricular
tachycardia
 Correction of electrolytes and acid base imbalance
 In patients with ischemic cardiomyopathy → ICD
implant is the option after r/o acute ischemia as
the cause
 In patients wit non ischemic cardiomyopathy
management is ICD implantation
New Methods
 Implantable ventricular assist devices
 Biventricular pacing (only in patient

with LBBB & CHF)
 Artificial Heart
Cardiac Transplant
 It has become more widely used since the

advances in immunosuppressive treatment
 Survival rate
 1 year 80% - 90%
 5 years 70%
Prognosis
 Annual mortality rate depends on patients
symptoms and LV function
 5% in patients with mild symptoms and mild
↓ in LV function
 30% to 50% in patient with advances LV
dysfunction and severe symptoms
 40% – 50% of death is due to SCD

Heart Failure: Kalaiselvan Ot

Uploaded by

Copyright:

Available Formats

Heart Failure: Kalaiselvan Ot

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Heart Failure: Kalaiselvan Ot

Uploaded by

Copyright:

Available Formats

Heart Failure

 It is commonly termed congestive heart

-Inappropriate work load (volume or pressure

• Restricted Filling: Pericardial diseases, Restrictive

 From hemodynamic stand point HF can

 HR , contractility, Arteriolar constriction 

 Renin-Angiotensin – Salt & water retention VR Vasoconstriction 

 interleukins &TNF May have roles in myocyte Apoptosis

Vasoconstriction VR  After load

 Changes in contractile proteins

• Low cardiac output symptoms

• Abdominal symptoms: Anorexia,nausea,

 Vibration of the ventricular wall by blood

 Pale, cold sweaty skin

 Systolic & Diastolic

 Size and shape of heart

 Function of both ventricles

 When CAD or valvular is suspected

 If heart transplant is indicated

 Renin-angiotensin-aldosterone system is activation

 Has comparable effect to ACE I

 Can be used in certain conditions when ACE I

 Non cardiac manifestations

 H/o embolic episodes

 Left ventricular apical thrombus

 Most common cause of SCD in these patients

 Patients with h/o sustained VT or SCD → ICD

 Implantable ventricular assist devices

 Biventricular pacing (only in patient

 It has become more widely used since the

You might also like